Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 14/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29290332 | 0.81 | MAPK14 (0.33) | MAPK14PTGS1PTGS2 | |
| SCHEMBL4450455 | 0.78 | ESR1 (0.46) | PTGS2KDM4ECYP3A4HPGDHSD17B10 | |
| SCHEMBL2781156 | 0.78 | PTGS2 (0.46) | PTGS2KDM4EHPGDTSHRHSD17B10 | |
| SCHEMBL2780142 | 0.78 | KIF11 (0.42) | MAPK14 | |
| SCHEMBL2779268 | 0.77 | BCAT2 (0.47) | PTGS2HPGDHSD17B10 | |
| SCHEMBL22261519 | 0.76 | KDM4E (0.41) | KDM4EHPGD | |
| SCHEMBL30172706 | 0.76 | KDM4E (0.41) | KDM4EHPGD | |
| SCHEMBL10843937 | 0.76 | MAPK14 (0.79) | MAPK14PTGS1PTGS2 | |
| SCHEMBL28395878 | 0.76 | MAPK14 (0.52) | MAPK14PTGS1PTGS2 | |
| SCHEMBL18099186 | 0.75 | CES1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721615-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2001009117-A1 | TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | ALLELLIX NEUROSCIENCE INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6162824-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ALLELIX NEUROSCIENCE INC. | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | RTF2, POLRMT, RTF1 | MAPK14 654/4885PTGS1 799/4885PTGS2 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.